Home » Stocks » HCM

Hutchison China MediTech Ltd. (HCM)

Stock Price: $29.25 USD -0.13 (-0.44%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 4.17B
Revenue (ttm) 227.98M
Net Income (ttm) -125.73M
Shares Out 148.90M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $29.25
Previous Close $29.38
Change ($) -0.13
Change (%) -0.44%
Day's Open 29.25
Day's Range 28.68 - 29.52
Day's Volume 126,540
52-Week Range 18.28 - 37.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

1 week ago - GlobeNewsWire

Hutchison China MediTech (HCM) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

1 week ago - Zacks Investment Research

— HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development — — HMPL-306 is the sixth innovative oncology drug candidate discovered in hou...

2 weeks ago - GlobeNewsWire

Hutchison China MediTech (NASDAQ: HCM) has agreed to sell its non-core and non-consolidated over-the-counter drug joint venture business to GL Capital Group. The sale of our shares in the joint venture,...

3 weeks ago - Benzinga

Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets Allows focus on China and global clinical development and market launches of key Oncology/Immu...

3 weeks ago - GlobeNewsWire

Hutchison China MediTech (NASDAQ: HCM) has initiated a Phase 1b/2 study of surufatinib combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab in patients with advanced solid tumors in the U.S. and Euro...

Other stocks mentioned: BGNE
3 weeks ago - Benzinga

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in comb...

3 weeks ago - GlobeNewsWire

Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT

1 month ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year e...

2 months ago - GlobeNewsWire

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Pha...

3 months ago - GlobeNewsWire

HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) ...

3 months ago - GlobeNewsWire

– Sulanda® is Chi-Med's first oncology drug brought to market without a partnership and the company's second oncology drug approved in China –

3 months ago - GlobeNewsWire

– Company plans to complete rolling submission in the first half of 2021 –

3 months ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executiv...

3 months ago - GlobeNewsWire

Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and support an...

Other stocks mentioned: BGNE
5 months ago - GuruFocus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

5 months ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first ...

5 months ago - GlobeNewsWire

― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ―

6 months ago - GlobeNewsWire

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that its New Drug Application (“N...

7 months ago - GlobeNewsWire

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration ...

7 months ago - GlobeNewsWire

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, it...

7 months ago - GlobeNewsWire

HONG KONG and FLORHAM PARK, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of sur...

7 months ago - GlobeNewsWire

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that it received scientific advice fro...

8 months ago - GlobeNewsWire

Hutchison China MediTech Limited (HCM) CEO Christian Hogg on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

– Strong global pipeline progress – three U.S. FDA 1 Fast Track Designations; surufatinib U.S. NDA 2 preparations underway; and initiation of global Phase III for fruquintinib –

8 months ago - GlobeNewsWire

HONG KONG and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administra...

8 months ago - GlobeNewsWire

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an am...

8 months ago - GlobeNewsWire

— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —

8 months ago - GlobeNewsWire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

9 months ago - GlobeNewsWire

LONDON, June 18, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Des...

10 months ago - GlobeNewsWire

LONDON, June 09, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ...

10 months ago - GlobeNewsWire

LONDON, June 04, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of...

10 months ago - GlobeNewsWire

LONDON, June 01, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S. F...

10 months ago - GlobeNewsWire

LONDON, April 17, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two Fast Trac...

1 year ago - GlobeNewsWire

LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fib...

1 year ago - GlobeNewsWire

Hutchison China MediTech (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Hutchison China MediTech Limited's (HCM) CEO Christian Hogg on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

1 year ago - GlobeNewsWire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

1 year ago - GlobeNewsWire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

1 year ago - GlobeNewsWire

Hutchison China MediTech Limited (HCM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Hutchison China MediTech.

1 year ago - Zacks Investment Research

LONDON, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivota...

1 year ago - GlobeNewsWire

Does Hutchison China MediTech (HCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (toripalimab...

1 year ago - GlobeNewsWire

LONDON, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38th Annual J...

1 year ago - GlobeNewsWire

LONDON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today announces that the Center for Drug Evaluation (CDE) of China’s National Medical Product...

1 year ago - GlobeNewsWire

LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Elunate® (fruquintinib capsules), its national class 1 targeted anticancer...

1 year ago - GlobeNewsWire

LONDON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug de...

1 year ago - GlobeNewsWire

About HCM

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It offers research and development services; and manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), pap... [Read more...]

Industry
Biotechnology
CEO
Christian Hogg
Employees
1,280
Stock Exchange
NASDAQ
Ticker Symbol
HCM
Full Company Profile

Financial Performance

In 2020, HCM's revenue was $227.98 million, an increase of 11.27% compared to the previous year's $204.89 million. Losses were -$125.73 million, 18.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for HCM stock is "Strong Buy." The 12-month stock price forecast is 40.01, which is an increase of 36.79% from the latest price.

Price Target
$40.01
(36.79% upside)
Analyst Consensus: Strong Buy